- Conditions
- Breast Cancer
- Interventions
- therapeutic conventional surgery, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 350
- States / cities
- Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,976
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Abaloparatide, Teriparatide
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 22,054 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acromegaly
- Interventions
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endocrine Therapy-Induced Alopecia, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Minoxidil, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
- Interventions
- Method(s)1 Attribution, Method(s)2 Attribution,
- Drug
- Lead sponsor
- DR. DIANE CHISESI NFS. MD. PHD.
- Other
- Eligibility
- 44 Years to 59 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Colorado Springs, Colorado
- Conditions
- Type 1 Diabetes
- Interventions
- ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Congenital Heart Disease, Disorder of Fetus or Newborn
- Interventions
- methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Transgenderism, Kidney Diseases, Kidney Injury
- Interventions
- p-aminohippurate clearance study, Iohexol infusion
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 17 Years to 30 Years
- Enrollment
- 22 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Prostate Cancer
- Interventions
- 3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
- Radiation · Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fairway, Kansas
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more
- Conditions
- Prostate Cancer
- Interventions
- monoclonal antibody muJ591
- Biological
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Participants
- Interventions
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Acute-graft-versus-host Disease
- Interventions
- Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Regular U-500 Insulin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- La Jolla, California • Boston, Massachusetts • New York, New York
- Conditions
- Primary Hypogonadism, Hypogonadotropic Hypogonadism
- Interventions
- Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Miami Gardens, Florida
- Conditions
- Prostate Cancer
- Interventions
- IMC-A12, Bicalutamide, Goserelin
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Menopause
- Interventions
- Hormone Replacement Therapy
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 45 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
- Interventions
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Adult Growth Hormone Deficiency
- Interventions
- Somapacitan
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
- Interventions
- Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy, Androgen Receptor Signaling Inhibitor
- Radiation · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
- Behavioral · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Knee Osteoarthritis
- Interventions
- Orthopaedic manual physical therapy, Corticosteroid Injection
- Procedure
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 38 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Tacoma, Washington